Multiple Studies Highlighting OGM Utility For Analysis of Cancer Biomarker Chromoanagenesis Published in Dedicated Issue of Methods in Molecular Biology
Bionano Genomics (NASDAQ: BNGO) announced the publication of multiple studies in Methods in Molecular Biology highlighting the advantages of optical genome mapping (OGM) in chromoanagenesis research. Chromoanagenesis, a catastrophic genomic event associated with complex cancer characteristics and poor prognosis, has been difficult to detect using traditional methods.
The publication includes four chapters demonstrating OGM's application in various cancer types, including acute myelogenous leukemia (AML), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL). The studies showcase OGM's ability to provide high-resolution, genome-wide views of structural variants crucial for understanding chromoanagenesis in cancer development.
Bionano Genomics (NASDAQ: BNGO) ha annunciato la pubblicazione di molteplici studi in Methods in Molecular Biology che evidenziano i vantaggi della mappatura ottica del genoma (OGM) nella ricerca sulla chromoanagenesi. Chromanagenesi, un evento genomico catastrofico associato a caratteristiche tumorali complesse e a una prognosi sfavorevole, è stato difficile da rilevare utilizzando i metodi tradizionali.
La pubblicazione comprende quattro capitoli che mostrano l'applicazione di OGM in vari tipi di cancro, tra cui leucemia mieloide acuta (LMA), mieloma multiplo (MM) e leucemia linfocitica cronica (LLC). Gli studi evidenziano la capacità di OGM di fornire viste ad alta risoluzione dell'intero genoma di varianti strutturali cruciali per comprendere la chromoanagenesi nello sviluppo del cancro.
Bionano Genomics (NASDAQ: BNGO) anunció la publicación de múltiples estudios en Methods in Molecular Biology que destacan las ventajas de la cartografía genómica óptica (OGM) en la investigación de la cromoanagenesis. Chromoanagenesis, un evento genómico catastrófico asociado con características complejas del cáncer y un pronóstico desfavorable, ha sido difícil de detectar con los métodos tradicionales.
La publicación incluye cuatro capítulos que demuestran la aplicación de OGM en varios tipos de cáncer, incluidos leucemia mieloide aguda (LMA), mieloma múltiple (MM) y leucemia linfocítica crónica (LLC). Los estudios muestran la capacidad de OGM para proporcionar vistas de alta resolución y a nivel del genoma de variantes estructurales cruciales para entender la Chromoanagenesis en el desarrollo del cáncer.
Bionano Genomics (나스닥: BNGO)은 Methods in Molecular Biology에 실린 다수의 연구가 광학 게놈 매핑(OGM)의 암 연구에서의 이점을 강조한다고 발표했다. Chromoanagenesis는 복잡한 암 특성과 불량한 예후와 관련된 파멸적 게놈 현상으로, 전통적 방법으로 탐지하기 어려웠다.
공개에는 네 개의 장이 포함되어 있으며, AML(급성 골수성 백혈병), MM(다발성 골수종), CLL(만성 림프구성 백혈병) 등 여러 암 유형에서 OGM의 적용을 보여준다. 연구들은 OGM이 암 발달에서 chromoanagenesis를 이해하는 데 중요한 구조적 변이를 고해상도로 전체 게놈 관찰이 가능하다는 것을 시연한다.
Bionano Genomics (NASDAQ: BNGO) a annoncé la publication de plusieurs études dans Methods in Molecular Biology mettant en évidence les avantages de la cartographie optique du génome (OGM) dans la recherche sur la chromoanagenèse. Chromanagenesis, un événement génomique catastrophique associé à des caractéristiques du cancer complexes et à un pronostic défavorable, a été difficile à détecter avec les méthodes traditionnelles.
La publication comprend quatre chapitres démontrant l'application de l'OGM dans divers types de cancer, y compris la leucémie myéloïde aiguë (LMA), le myélome multiple (MM) et la leucémie lymphoïde chronique (LLC). Les études mettent en évidence la capacité de l'OGM à fournir des vues à haute résolution et à l'échelle du génome des variantes structurelles cruciales pour comprendre la chromoanagenèse dans le développement du cancer.
Bionano Genomics (NASDAQ: BNGO) hat die Veröffentlichung mehrerer Studien in Methods in Molecular Biology angekündigt, die die Vorteile der optischen Genomkartierung (OGM) in der Chromoanagenese-Forschung hervorheben. Chromoanagenesis, ein katastrophales genomisches Ereignis, das mit komplexen Krebsmerkmalen und schlechter Prognose verbunden ist, war mit herkömmlichen Methoden schwer zu erkennen.
Die Veröffentlichung umfasst vier Kapitel, die die Anwendung von OGM in verschiedenen Krebsarten demonstrieren, darunter akute myeloische Leukämie (AML), Multiples Myelom (MM) und chronische lymphatische Leukämie (CLL). Die Studien zeigen die Fähigkeit von OGM, hochauflösende, genomweite Ansichten von strukturellen Varianten bereitzustellen, die entscheidend für das Verständnis der Chromoanagenese bei der Krebsentwicklung sind.
Bionano Genomics (NASDAQ: BNGO) أعلنت عن نشر عدة دراسات في Methods in Molecular Biology تبرز مزايا التخطيط الجينومي البصري (OGM) في أبحاث Chromoanagenesis. Chromoanagenesis، حدث جيني كارثي مرتبط بسمات سرطان معقدة وتوقعات سيئة، كان من الصعب اكتشافه باستخدام الطرق التقليدية.
يشمل النشر أربعة فصول توضح تطبيق OGM في أنواع سرطان مختلفة، بما في ذلك لوكيميا نخاعية حادة (AML)، الورم النقوي المتعدد (MM)، واللوكيميا المزمنة اللمفاوية (CLL). تُظهر الدراسات قدرة OGM على توفير رؤًى عالية الدقة وعلى مستوى الجينوم للمتغيرات البنيوية الحاسمة لفهم Chromoanagenesis في تطور السرطان.
Bionano Genomics（纳斯达克股票代码：BNGO）宣布在 Methods in Molecular Biology 上发表多项研究，强调光学基因组映射（OGM）在染色体大爆发（Chromoanagenesis）研究中的优势。Chromoanagenesis，一种与复杂癌症特征及不良预后相关的灾难性基因组事件，传统方法很难检测到。
该出版物包含 四章，展示了 OGM 在多种癌症类型中的应用，包括急性髓性白血病（AML）、多发性骨髓瘤（MM）和慢性淋巴细胞性白血病（CLL）。研究显示 OGM 能提供高分辨率、覆盖全基因组的结构变异视图，这对理解癌症发展中的 Chromoanagenesis 至关重要。
- OGM technology demonstrates superior capability in detecting complex genomic rearrangements compared to traditional methods
- Research expansion into multiple cancer types (AML, MM, CLL) shows broader application potential
- Publication in a respected scientific book series validates the technology's importance in cancer research
- None.
Insights
Bionano's OGM technology gains scientific validation for detecting complex cancer-associated genomic rearrangements, potentially expanding its clinical applications.
The publication of multiple studies in Methods in Molecular Biology featuring Bionano's optical genome mapping (OGM) technology represents significant scientific validation of the platform's utility in chromoanagenesis research. Chromoanagenesis—encompassing catastrophic genomic events like chromothripsis, chromoplexy, and chromoanasynthesis—is associated with complex karyotypes, treatment resistance, and poor prognosis in cancer patients.
What makes this development particularly notable is that OGM appears to overcome detection limitations inherent in traditional cytogenetic and sequencing methods. The technology's ability to provide genome-wide views of structural variants at high resolution enables precise identification of complex rearrangements that conventional methods often miss.
The expansion of OGM applications into multiple cancer types—from the initial acute myelogenous leukemia (AML) studies to now include multiple myeloma (MM) and chronic lymphocytic leukemia (CLL)—suggests growing recognition of the technology's value in hematologic malignancy research. Furthermore, the development of novel workflows like dam assisted fluorescent tagging demonstrates continued technical innovation around the platform.
For Bionano, this scientific recognition helps establish OGM as an emerging standard for analyzing complex genomic rearrangements in cancer research. As chromoanagenesis becomes better understood as a prognostic indicator and potential therapeutic target, technologies that reliably detect these events may see increased adoption in both research and clinical settings, potentially expanding Bionano's market opportunities in precision oncology.
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that an issue of the book series Methods in Molecular Biology dedicated to studies of the catastrophic genome rearrangement known as chromoanagenesis was published with multiple studies highlighting the advantages of optical genome mapping (OGM) in chromoanagenesis research.
According to research, chromoanagenesis refers to a catastrophic genomic event frequently associated with highly complex karyotypes, extensive clonal heterogeneity, treatment resistance, and poor prognosis. It includes events such as chromothripsis, chromoplexy, and chromoanasynthesis, all of which play a significant role in cancer development. Detecting chromoanagenesis has been challenging with traditional cytogenetic and sequencing methods because of the size, heterogeneity, and complexity of these rearrangements. OGM can provide a genome-wide view of structural variants at high resolution, enabling precise identification and characterization of the genome variation underpinning chromoanagenesis.
The first study to use OGM in studies of chromoanagenesis centered on acute myelogenous leukemia (AML) and was published in January 2025. The four chapters published in this book series highlight the use of OGM in chromoanagenesis research and the expansion into new cancer types such as multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), as well as the proliferation of novel workflows such as dam assisted fluorescent tagging of chromatin accessibility, which is a hybrid method for highly detailed spatial and structural analysis of chromatin assemblies.
“Chromoanagenesis appears to be a key driver of genomic complexity in hematologic malignancies, with the potential to signal likelihood of poor prognosis and the possibility of treatment resistant disease,” said Erik Holmlin, PhD, president and CEO of Bionano. “OGM can provide the resolution necessary to detect and resolve these events, helping researchers explore their impact on disease biology and therefore devise potential management strategies, including therapeutic intervention. We are impressed to see the growth in studies dedicated to this area, suggesting a broad new area of application of OGM across multiple disease indications.”
The full volume is available online: https://link.springer.com/book/10.1007/978-1-0716-4750-9
About Bionano Genomics
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.
For more information, visit www.bionano.com or www.bionanolaboratories.com.
Bionano’s products are for research use only and not for use in diagnostic procedures.
Forward-Looking Statements of Bionano Genomics
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things; the ability and utility of the OGM to prove useful in the analysis of chromoanagenesis; the ability and utility of OGM to overcome the challenges of traditional cytogenetics and sequencing for analyzing chromoanagenesis; the ability of OGM to provide a genome-wide view of structural variants at high resolution, enabling precise identification and characterization of the genome variation underpinning chromoanagenesis; the ability of OGM to resolve chromoanagenesis; and any other statements that are not of historical fact. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the failure of OGM to prove useful in the analysis of chromoanagenesis; the failure of OGM to overcome the challenges of traditional cytogenetics and sequencing for analyzing chromoanagenesis; the failure of OGM to provide a genome-wide view of structural variants at high resolution, enabling precise identification and characterization of the genome variation underpinning chromoanagenesis; the failure of to resolve chromoanagenesis ; the failure of OGM to outperform legacy cytogenomic methods; future publications that contradict the findings of the publication referenced in this press release; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a “going concern,” which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the impact of adverse geopolitical and macroeconomic events, such as the ongoing conflicts between Ukraine and Russia and Israel and Gaza and uncertain market conditions, including inflation, tariffs, and supply chain disruptions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; study results that differ or contradict the results mentioned in this press release; the risk that we are not able to complete a strategic transaction that would increase stakeholder value; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties including those described in our filings with the Securities and Exchange Commission (“SEC”), including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q and in other filings subsequently made by us with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as may be required by law.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
Kelly Gura
Gilmartin Group
+1 (212) 229-6163
IR@bionano.com
FAQ
What is the significance of chromoanagenesis in cancer research that BNGO's technology helps study?
Which cancer types are being studied using Bionano Genomics' OGM technology?
How does Bionano's OGM technology differ from traditional methods in studying chromoanagenesis?
What are the potential clinical implications of BNGO's chromoanagenesis research?
